|
LEADER
Lower Extremity Arterial Disease Event Reduction
Ongoing trial
 |
Author(s) |
Meade TW
|
 |
Title(s) |
Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease
|
|
Reference(s) |
Curr Control Trials Cardiovasc Med 2001;21:195-204 |
|
Disease |
Cardiovascular disease
|
|
Purpose |
To evaluate whether a fibrate reduces the incidence of major ischaemic heart disease and stroke in men with lower extremity arterial disease
|
|
Study design |
Randomised, double-blind, placebo-controlled
|
|
Follow-up |
3 years
|
|
Patients |
1568 men (783 bezafibrate, 785 placebo), mean age 68.6 years, with lower extremity arterial disease
|
|
Treatment regimen |
Bezafibrate, 400 mg/day for men with serum creatinine < 135 mol/l, bezafibrate 400 mg on alternate days for men with serum creatinine 135-149 mol/l (later changed to > 155 mol/l), or placebo
|
|
Results |
Not yet available
|
|
|
|
